Kornimate/medical-research-clean huggingface dataset:
therapeutic effects of galvanic vestibular stimulation (gvs) on spatial neglect

Conditions: Spatial Neglect After Right Brain-damage

Summary: the purpose of this study is to determine whether galvanic vestibular stimulation is effective in the treatment of spatial neglect after right brain-damage.


Eligibility criteria:
inclusion criteria: * spatial neglect after unilateral ischemic infarction or unilateral haemorrhage exclusion criteria: * chronic epilepsy * metallic implants (including pacemakers) * brain tumors * scalp inflammation * degenerative disease

Keywords: spatial neglect galvanic vestibular stimulation as therapy
cognitive behavioral therapy and light therapy

Conditions: Pulmonary Hypertension; Insomnia; Fatigue

Summary: cognitive behavioral therapy (cbt-i) is a common treatment for insomnia that does not use medications. while cbt-i is effective for insomnia, it does not tend to improve the waking symptom of fatigue. another treatment, bright light therapy, is used for treating seasonal depression and sleep disorders, and may improve fatigue and physical activity in individuals with pah. the purpose of this study to assess the effects of bright light therapy compared to cbt-i to treat insomnia and fatigue in patients with pah.

in a single site, 3-arm (cognitive behavioral therapy \[cbt-i\] group; bright light therapy group; standard of care group), parallel, randomized controlled trial we will enroll 36 subjects (n=12 per group) to assess the feasibility of bright light therapy compared to cbt-i in subjects with pulmonary arterial hypertension (pah) to treat insomnia (difficulty initiating sleep or maintaining sleep) and fatigue. * to assess the recruitment and retention rates of cbt-i and bright light therapy. * to compare the effects of cbt-i and bright light therapy to standard of care on (insomnia and fatigue severity) and secondary (wake after sleep onset and sleep onset latency) outcomes. * to test the effects of cbt-i and bright light therapy to standard of care on the secondary outcome physical activity. * to test the effects of cbt-i and bright light therapy to standard of care on the secondary outcomes: depression, dyspnea and qol.

Eligibility criteria:
inclusion criteria: * pah diagnosis * insomnia * fatigue exclusion criteria: * untreated obstructive sleep apnea * subjects with left-sided valvular disease * hospitalized or acutely ill * any eye disease such as, but not limited to, cataracts, glaucoma, retinal disorders (e.g. macular degeneration), or previous eye surgery * subjects with photosensitivity (e.g. epilepsy) * manic-depressive psychosis or bipolar disorder
pilot rct feasibility study: cancer and t2d

Conditions: Diabetes Mellitus, Type 2; Cancer

Summary: the purpose of this study is to test a nurse-led intervention for adults with newly diagnosed cancer and undiagnosed/newly diagnosed type-2 diabetes

specific aim 1: to examine study feasibility of a nurse-led intervention for adults with newly diagnosed cancer and t2d. we define feasibility indicators as: (a) efficient study recruitment is possible given prevalence of t2d (diagnosed and undiagnosed) in uf patients with newly diagnosed cancer; (b) retention rates in both groups ≥80% to indicate that the study design and methods are adequately patient-centered; (c) identified barriers to and facilitators of a nurse-led intervention are respectively modifiable or optimizable; and (d) patient acceptability scores \>8 for the study procedures. we hypothesize that we will recruit up to 40 patients within 18 months and retain ≥ 80% of patients in all groups; minor but important revisions will be required to resolve issues identified with using the nurse-led intervention; and 80% of patients from both groups who complete the study will report that the burden of the study is acceptable through their retention in the study. specific aim 2: to determine the variation in hba1c at baseline and at the end of the three-month intervention period in each of the two study groups.

Eligibility criteria:
inclusion criteria: * a) 18 years and older * b) using pathology reports, a new diagnosis of a solid tumor cancer or lymphoma within the past 3 months * c) patients being treated with curative intent or those with a prognosis estimated to be \>2 years, as best assessed by the oncologist. * d) first medical oncology outpatient visit at uf within the past 3 months * e) plans to continue cancer care at uf * f) speaks and reads english * g) can comply with study related procedures, per the treating oncologist or advanced practice provider exclusion criteria: * a) diagnosis of leukemia or pancreatic cancer as the new cancer diagnosis * b) being treated for t2d for \> than 3 months * c) egfr \<45ml/minute/1.73m2 * d) liver insufficiency (defined as liver enzymes over 5 times the upper limit of normal or clinical sequelae of advanced cirrhosis as documented by the treating oncologist or advanced practice providers. * e) active infection requiring systemic antibiotics * f) taking systemic steroids of more than 1-week duration. must have stopped \>3 days prior to study enrollment. note, inhaled or topical steroids are not exclusion criteria. * g) planning to receive cancer care at a location outside of uf * h) enrolled in another study with similar outcomes. * i) currently taking metformin or known inability to tolerate it
evaluating the effect of isotretinoin in regulatory t-cell function in adverse cutaneous drug eruptions (acdes): a pilot study

Conditions: Toxic Epidermal Necrolysis

Summary: the purpose of this study is to determine whether isotretinoin is helpful in treating patients with an adverse cutaneous drug eruption known as toxic epidermal necrolysis (ten).

toxic epidermal necrolysis (ten) is a potentially life-threatening skin disorder characterized by widespread redness, blistering and peeling of skin. currently, supportive care in the standard treatment for patients with ten. isotretinoin, an fda-approved medication commonly used for treating severe acne induces differentiation of certain inflammatory cells and thus may potentially be helpful in treating patients with ten. this is a randomized, placebo-controlled, double-blind, pilot study comparing the efficacy and safety of isotretinoin versus placebo in treating subjects with toxic epidermal necrolysis (ten). approximately 40 subjects who satisfy all inclusion and exclusion criteria will be randomly assigned in a 1:1 ratio to either isotretinoin or placebo which they will take for up to 14 days. the end of the study is defined as the time the subject is discharged from the hospital. participants will primarily be assessed for percent body surface affected (bsa) and number of days of hospitalization.

Eligibility criteria:
inclusion criteria: 1. 18 - 69 years of age 2. has biopsy-proven toxic epidermal necrolysis (ten) 3. if female, should not be of childbearing potential defined as: * have not had menstrual periods for 12 months in a row (menopause) or * had bilateral oophorectomy or total hysterectomy or * have a ovarian disorder that would make pregnancy not possible exclusion criteria: 1. unknown hiv status and unwilling to undergo hiv testing 2. women of childbearing potential 3. pregnancy 4. breastfeeding 5. fasting serum triglyceride levels \>25% of upper limit of normal 6. aspartate aminotransferase (ast), alanine aminotransferase (alt), and alkaline phosphatase levels \>2× upper limit of normal (uln) 7. known allergy to isotretinoin 8. history of suicidal attempt, psychosis, major depression or other serious mood disorders 9. currently taking vitamin a supplements, tetracyclines, phenytoin, corticosteroids, ivig or st. john's wort 10. has any condition that, in the opinion of the investigator, would make participation not be in the best interest (for example, compromise the well-being) of the participant or that could prevent, limit, or confound the protocol-specified assessments 11. participation in an interventional study within the past 30 days.

Keywords: ten
comparison of three motor-cognitive training programs

Conditions: Cognitive Decline

Summary: understanding how to delay age-related physical and mental declines is an issue for aging research. it has been shown that isolated aerobic, coordination and cognitive training improve brain functions and cognitive performances. moreover, the combination of them leads to greater effects. different combination modalities are possible: training programs demanding cognitive resources within the activity performed in a natural environment like nordic walking (or tai chi, dance...); or as in a conceptually-grounded circuit training where training components are systematically combined and their intensity controlled. the aim of this study is to compare three training programs: a nordic walking one (nw), and two conceptual grounded, circuits training (ct-c; ct-fit). ct-c implemented by dual-task (dt) exercises, while ct-fit characterized by cognitive charge embodied in the movements through the use of technology. an improvement in physical, motor, and cognitive functions is expected by all three groups. however, our primary hypothesis is that the ct-fit will impact executive functions more. 45 healthy independent living community dwellers participants aged 65 to 80 will be recruited. participants will be included after a general medical examination (geriatric screening and cycle-ergometer maximal effort test). the main exclusion criteria are signs of cognitive impairment, (mmse \<26/30), and physical impairments. participants will be randomly divided into the 3 groups (nw, ct-c, ct-fit): the training program will last 8 weeks, 1 hour 3 times a week. pre and post-tests will include cognitive assessment (moca; tmt; stroop task, happy neuron™ working memory test, rey complex figure copy task and dual-task capacities through the dt-otmt); motor fitness assessment (bipedal upright standing, unipedal balance test, walking speed and size of the base of support, timed up \& go, chair sit and reach test and four square stepping test) and physical assessment (10 m incremental shuttle walking test, maximal handgrip force, 30s chair rise stand). improving cognitive functions by adding new technology embodied in a systematically combined training (exergame), would result to be the best solution to optimize training for aging people.


Eligibility criteria:
inclusion criteria: * considered apt for moderate physical activity practice (validated by a maximal vo2 cycle-ergometer test by a cardiologist) * sedentary or moderately active (objectified by the categories obtained at the ipaq) * cognitively healthy (objectified by a score at the mmse of 26 and above) exclusion criteria: * colorblindness * uncorrected earing and/or visual impairment * presence of a known psychiatric or neurologic condition * under psychotropic treatment or beta-blockers

Keywords: aging, cognition, cognitive-motor training, nordic walking
oct-guided lalak in children

Conditions: Corneal Opacity

Summary: the primary goal of the trial is to determine if laser-assisted lamellar anterior keratoplasty (lalak) will reduce the risks of post-operative complications such as adhesions, glaucoma and cataract that are associated with pediatric penetrating keratoplasty (pk).

there is a great need for lamellar keratectomy in the treatment of congenital opacities because the rejection rate in pediatric pk is 4-5 times higher than in adults. in addition, the intraocular inflammatory reaction in infants often leads to synechiae, glaucoma, and cataract. because lalak does not penetrate the eye and preserves the host endothelium, it could reduce the risk of these complications. keratoplasty must be performed at this early age to prevent amblyopia. in this study, oct-guided lalak will be performed in patients whose vision is limited by opacity in the anterior 2/3 of the cornea. the objective is to determine if lalak will provide an equal or better visual outcome than traditional pk without the associated post-operative complications.

Eligibility criteria:
inclusion criteria: * vision limited by opacity in the anterior 2/3 of the corneal stroma * posterior opacity and endothelial defect must be less than 1 mm in diameter exclusion criteria: * presence of cataract * presence of adhesions of the iris or lens to the cornea * inability/unwillingness of parents to give informed consent * inability of parents to commit to required visits to complete the study

Keywords: cornea opacity congenital
french validation orebro musculoskeletal pain screening questionnaire (ompsq) questionnaire

Conditions: Acute Low Back Pain; Chronic Low Back Pain

Summary: low back pain is a very common disease. among the persons suffering of acute low back pain, about 10% are at risk of developping chronic pain. a screening questionnaire assessing this risk has been developed and validated in swedish and english (orebro musculoskeletal pain screening questionnaire, linton, 2003). the aim of our study is to validate a french translation of this questionnaire. patients suffering from acute low back pain will be asked to fill in several questionnaires at day 0, and 6 and 12 month later.


Eligibility criteria:
inclusion criteria: * all consecutive patients presenting at the clinical care setting with acute low back pain * pain lasting for less than three months * cumulated sick leave less thant six months exclusion criteria: * unability to sufficiently read and understand french * presence of red flags as according to the new zealand acute low back pain guide

Keywords: low back pain
root biomodification with citric acid and tetracycline improves the outcomes of root coverage

Conditions: Gingival Recession

Summary: the aim of this study is to investigate the effects of the application of a citric acid + tetracycline gel solution during 90 or 180 seconds compared to no conditioning in the outcomes of treatment of miller's class i or ii recession defects by subepithelial connective tissue graft.

adult patients showing miller's class i or ii recession defects requiring root coverage were recruited to participate in the study. all patients were submitted to non surgical periodontal therapy consisting of scaling and root planing, prophylaxis, and oral hygiene instruction in order to reduce/eliminate gingival inflammation. after that, patients were randomly allocated to three different treatment groups based on root conditioning: g0- no conditioning; g90- root conditioning for 90 seconds; g180- root conditioning for 180 seconds. allocation was defined by a software. root coverage was performed by subepithelial connective tissue graft (sctg) in all treated sites by the same operator, who performed the indicated root treatment. periodontal parameters were investigated at baseline and at 1, 3, 6 and 12 months post-operatively by a blinded trained expertise different from operator and included: pocket depth, recession height, clinical attachment level, width of keratinized gingiva, sulcular bleeding index and plaque index. hypersensitivity at recession sites was also investigated at baseline and at 7 days, 14 days, 1, 3, 6 and 12 months after treatment according to visual analogic scale (vas).

Eligibility criteria:
inclusion criteria: * presence of miller's class i or ii recession extending 2-5 mm apical to cej requiring root coverage for the following reasons: esthetics, progression of recession or hypersensitivity. exclusion criteria: * smokers; * pregnants; * routine use of anti-convulsants, anti-hypertensive or cyclosporine; * uncontrolled systemic diseases (e.g.: diabetes mellitus); * systemic conditions that requires antibiotic prophylaxis (e.g.: history of bacterial endocarditis; rheumatoid arthritis; prosthetic valves); * antibiotics, steroidal or non-steroidal anti-inflammatory intake in the 6-month previous period.

Keywords: gingival recession soft tissue root biomodification root coverage citric acid tetracycline
study on efficacy of add on selenium in mild-to-moderate graves ophthalmopathy

Conditions: Thyroid Eye Disease; Graves Ophthalmopathy

Summary: the study on efficacy of add on selenium in mild-to-moderate graves ophthalmopathy: a randomized control trial.; the study aims to evaluate the response of adding selenium in patients with graves ophthalmopathy, focusing on improving quality of life, cas scoring, and thyroid status. the methodology involves a randomized control trial with a sample size of 78 patients. patients meeting specific criteria will receive either standard treatment with anti thyroid drugs and vitamin b complex or add on selenium with vitamin b complex for 6 months. outcome measures include cas score reduction, thyroid function improvement, and quality of life enhancement. the study will last 18 months, with various investigations and ethical considerations outlined. the document emphasizes the importance of early diagnosis of graves ophthalmopathy to prevent vision loss and deformity, highlighting the significance of informed patients and healthcare professionals regarding ted symptoms and risk factors.

the study on efficacy of add on selenium in mild-to-moderate graves ophthalmopathy: a randomized control trial. the study aims to evaluate the response of adding selenium in patients with graves ophthalmopathy, focusing on improving quality of life, cas scoring, and thyroid status. the methodology involves a randomized control trial with a sample size of 78 patients. patients meeting specific criteria will receive either standard treatment with anti thyroid drugs and vitamin b complex or add on selenium with vitamin b complex for 6 months. outcome measures include cas score reduction, thyroid function improvement, and quality of life enhancement. the study will last 18 months, with various investigations and ethical considerations outlined. the document emphasizes the importance of early diagnosis of graves ophthalmopathy to prevent vision loss and deformity, highlighting the significance of informed patients and healthcare professionals regarding ted symptoms and risk factors.

Eligibility criteria:
inclusion criteria: * patients with mild-to-moderate grave's ophthalmopathy in age group \>18years with only one or more : * retraction of lid \<2 mm * mild soft tissue involvement * proptosis of \<=3 mm * corneal exposure that responds to lubricating eyedrops. * patients with cas \< = 4 * patients diagnosed with hyperthyroidism converted to euthyroid since 2 months with anti thyroid drugs. * those who are willing to follow the advised treatment and timely follow ups. exclusion criteria: * treatment with any steroid (intravenous, oral or topical) for any condition within 3 weeks before presentation. * any treatment with rituximab * any earlier treatment with teprotumumab. * any treatment with monoclonal antibody within 3months before presentation. * lactating or pregnant women

Keywords: thyroid eye disease graves ophthalmopathy
an intraoperative guidance platform for radio frequency ablation

Conditions: Hepatocellular Carcinoma

Summary: this study tests the hypothesis that use of the research rfa (radiofrequency ablation) physics library will result in more frequent technical success (complete necrotization of target tissues) compared to ablations conducted without computer guidance. the rfa physics library -- a planning and guidance platform (pgp) (ne scientific, llc) -- will be used to support percutaneous liver rfa under ct-guidance by assisting physicians in the identification of ablation targets, assessment of proper ablation probe placement, and projection of the created ablation zones on the ct image.

patients referred for curative ablation of an hcc by consensus recommendation of the multidisciplinary liver tumor clinic at a 400-bed academic cancer center from june 2018 through december 2021 were considered for participation in the study. inclusion criteria : patient : over 18 years old , ble to provide informed consent, expected survival \>1 year lesion: hcc, \>2 cm in diameter, located \> 1 cm from any other lesion. procedure : completed using the support of the accublate simulation software. software detail at : hoffer ek, borsic a, patel sd. validation of software for patient-specific real-time simulation of hepatic radiofrequency ablation. acad radiol. 2022 oct;29(10):e219-e227. doi: 10.1016/j.acra.2021.12.018. pmid: 35039220; pmcid: pmc9276838 treatment: ct-guided rfa with boston scientific leveen system, rf3000 generator. . prophylactic antibiotic general anesthesia; imaging during suspended ventilation, no peep ablation per manufacturer's protocol. target : tumor + 5 mm margin planning, targeting, intraprocedural repositioning, assessment of ablation coverage using software simulation in conjunction with manufacturer's data map. tract ablation follow-up clinic visit with contrast-enhanced cross-sectional imaging (mri or ct) at 3 months, then every 3 months x 2 years. data review for complications, progression of liver disease, evidence of local, regional, or metastatic disease, and additional interventions. outcome measures: primary : local tumor progression secondary: hepatic tumor progression

Eligibility criteria:
inclusion criteria: 1. ≥ 18 years of age 2. presence of hepatocellular carcinoma with a size equal or larger than 2cm. 3. scheduled for ct-guided thermal ablation under general anesthesia 4. able to provide written, informed consent exclusion criteria: 1. absolute of relative contraindication to mri: 1. the presence of an electronic implant, such as a pacemaker not approved for mri 2. the presence of a metal implant, such as an aneurysm clip not approved for mri 3. claustrophobia 4. the presence of other contraindication(s), such as inability to comfortably lie flat, history of working with metal, other implanted hardware or shrapnel 2. target tumor adjacent to or within prior ablated or resected site. 3. serious psychiatric illness not adequately controlled to permit patient cooperation to obtain an mri

Keywords: radiofrequency ablation
phase iii study of rosuvastatin and fenofibrate versus rosuvastatin in mixed dyslipidemia

Conditions: Mixed Dyslipidemias

Summary: efficacy and safety of combination therapy of rosuvastatin and fenofibrate versus rosuvastatin monotherapy in mixed dyslipidemia patients: a randomized, multi-center, double-blind, phase 3 study


Eligibility criteria:
inclusion criteria: * 19 \~ 80 years old * high risk patient to coronary heart disease * at visit 1(screening) 1. treated with rosuvastatin 10mg monotherapy 4weeks prior to this study 2. 110 mg/dl ≥ ldl-c, 200 mg/dl ≤ tg ≤ 500 mg/dl * at visit 2 (baseline), 110 mg/dl ≥ ldl-c, 200 mg/dl ≤ tg ≤ 500 mg/dl exclusion criteria: * ast or alt \> 2x uln * patients with uncontrolled hyperthyroidism (tsh\>1.5x uln) * patients with uncontrolled diabetes (hba1c ≥ 9%) * patients with uncontrolled hypertension(sbp\>160mmhg or dbp\>95mmhg) * patients with congestive heart failure(nyha class iii\~iv) or uncontrolled arrhythmia within 6 months * patients treated with any investigational drugs within 3 months at the time consents are obtained * not eligible to participate for the study at the discretion of investigator